Half of the European population is overweight and at a higher risk of developing type 2 diabetes. Our portfolio company Oviva was founded in 2014 by a team of health and technology experts. The three founders Kai Eberhardt (CEO), Manuel Baumann (CTO), and Mark Jenkins (UK Managing Partner & Medical Director) recognized that, despite these circumstances, there were no personalized, long-term treatment options available to address this important issue.
They developed a smart app that combines personal advice by a dietitian, the option to record relevant data entries such as meals, physical activity, and weight. But that’s not all, because the app enables a regular exchange with the corresponding dietitian via chat and provides the user with helpful learning content.
Oviva helps and enables its patients to lead a healthier life, relieves pressure on doctors to advise on weight and lifestyle, and ultimately leads to savings for the health system. The company works together with statutory health insurances and national health systems and operates in Switzerland (headquarter), Germany, the UK and France. The Oviva app has been certified as a medical device since November 2020.
As a long-term investor with a track record of creating successful and sustainable businesses, our goal is to deliver attractive strategic and financial returns to our investors.